. Author manuscript; available in PMC: 2024 May 21.

Published in final edited form as: J Clin Virol. 2015 Jul 13;70:97–100. doi: 10.1016/j.jcv.2015.07.005

Table 2.

Comparison of reactivity of DPP^® HIV and other antibody-based rapid tests during early stages of HIV-1 infection.

	DPP^® HIV assay
	Reactive(n)	Non-Reactive(n)	p value
Oraquick-R	62	1	0.0001*
Oraquick-NR	19	148
Complete-R	72	1	0.0269*
Complete-NR	9	148
Unigold-R	62	10	0.1374
Unigold-NR	19	139
Statpak-R	74	1	0.0771
Statpak-NR	7	148
Reveal-R	75	5	1
Reveal-NR	6	144
Multispot-R	78	12	0.039*
Multispot-NR	3	137

The numbers (n) reflect the paired comparison analysis of 230 plasma specimens from 26 seroconverters. The reactivity of DPP^® HIV was compared to historical data generated with each of the following FDA-approved rapid tests: OraQuick ADVANCE (Oraquick), Uni-Gold Recombigen HIV (Unigold), Reveal G2 and G3 Rapid HIV-1 antibody test (Reveal), Multispot HIV-1/HIV-2 rapid test (Multispot), Clearview HIV-1/2 STAT-PAK (Statpak), and Clearview HIV-12/ Complete (Complete). The p values were obtained from the McNemar’s statistical analysis. The values with an asterisk indicate a statistically significant difference in reactivity between tests during early stages of HIV-1 infection. R: reactive; NR: non-reactive.